8.71
Schlusskurs vom Vortag:
$8.91
Offen:
$8.6
24-Stunden-Volumen:
121.32K
Relative Volume:
0.32
Marktkapitalisierung:
$200.92M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-102.09M
KGV:
-8.2952
EPS:
-1.05
Netto-Cashflow:
$-108.72M
1W Leistung:
+18.50%
1M Leistung:
+74.55%
6M Leistung:
+148.86%
1J Leistung:
+31.77%
Dbv Technologies Adr Stock (DBVT) Company Profile
Firmenname
Dbv Technologies Adr
Sektor
Branche
Telefon
33(0)155427878
Adresse
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Vergleichen Sie DBVT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
DBVT
Dbv Technologies Adr
|
8.73 | 200.92M | 0 | -102.09M | -108.72M | -1.05 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
488.84 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
582.37 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
599.96 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.63 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
253.95 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-01-04 | Hochstufung | Societe Generale | Hold → Buy |
2022-12-16 | Herabstufung | Goldman | Neutral → Sell |
2022-05-10 | Herabstufung | Goldman | Buy → Neutral |
2021-09-14 | Hochstufung | Societe Generale | Hold → Buy |
2021-01-22 | Herabstufung | Societe Generale | Hold → Sell |
2020-11-02 | Hochstufung | Societe Generale | Sell → Hold |
2020-08-06 | Herabstufung | Societe Generale | Buy → Sell |
2020-08-05 | Bestätigt | H.C. Wainwright | Buy |
2020-03-17 | Herabstufung | Stifel | Buy → Hold |
2020-01-09 | Hochstufung | Stifel | Hold → Buy |
2019-12-16 | Eingeleitet | Citigroup | Buy |
2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2019-06-17 | Eingeleitet | Goldman | Buy |
2018-12-20 | Herabstufung | Barclays | Overweight → Equal Weight |
2018-12-20 | Herabstufung | BofA/Merrill | Buy → Underperform |
2018-12-20 | Herabstufung | Jefferies | Buy → Hold |
2018-12-20 | Herabstufung | Stifel | Buy → Hold |
2017-10-31 | Hochstufung | Societe Generale | Sell → Hold |
2017-10-24 | Herabstufung | Societe Generale | Buy → Sell |
2017-10-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2017-06-23 | Eingeleitet | Deutsche Bank | Buy |
2017-03-16 | Hochstufung | Societe Generale | Hold → Buy |
2016-09-26 | Eingeleitet | JMP Securities | Mkt Outperform |
2015-12-03 | Eingeleitet | Barclays | Overweight |
2015-10-23 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Dbv Technologies Adr Aktie (DBVT) Neueste Nachrichten
DBV Technologies (NASDAQ:DBVT) & Vaxcyte (NASDAQ:PCVX) Critical Contrast - Defense World
DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com - Defense World
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document - Informazione.it
DBV Technologies S.A. SEC 10-K Report - TradingView
DBV Technologies Completes Dual-Market Financial Filings for 2024 - Stock Titan
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView
DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com - Defense World
European ADRs Show Mixed Fortunes In US Market - Finimize
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView
DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com - Defense World
European ADRs See Mixed Results With Biopharma Leading Gains - Finimize
Why DBV Technologies (DBVT) Stock Is Skyrocketing - Benzinga
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading - TradingView
US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets' - Benzinga
DBV Technologies announces up to $307M financing to advance Viaskin Peanut program - MSN
DBV Technologies Announces Financing of up to $306.9 - GlobeNewswire
Major Breakthrough: $306.9M Funding Powers Revolutionary Peanut Allergy Patch to FDA Finish Line - Stock Titan
DBV Technologies (NASDAQ:DBVT) vs. Jasper Therapeutics (NASDAQ:JSPR) Head to Head Comparison - Defense World
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView
DBV Technologies faces cash shortage, stock drops By Investing.com - Investing.com South Africa
DBV Technologies faces cash shortage, stock drops - Investing.com
Major FDA Breakthrough: DBV's Peanut Allergy Treatment Path Accelerates Despite Cash Concerns - Stock Titan
DBV Technologies Secures Agreement with FDA on Safety - GlobeNewswire
REG-DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results... - TradingView
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down for Week - TradingView
DBV Technologies’ SWOT analysis: peanut allergy patch stock faces crucial trials By Investing.com - Investing.com South Africa
DBV Technologies’ SWOT analysis: peanut allergy patch stock faces crucial trials - Investing.com
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Lower Wednesday - TradingView
European Equities Traded in the US as ADRs Fall in Tuesday Trading - TradingView
JMP reiterates DBV Technologies stock with $10 target - Investing.com
European Equities Traded in the US as American Depositary Receipts Surge Higher in Monday Trading - TradingView
DBV Technologies (DBVT) Projected to Post Quarterly Earnings on Thursday - MarketBeat
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
Finanzdaten der Dbv Technologies Adr-Aktie (DBVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Dbv Technologies Adr-Aktie (DBVT) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Mohideen Pharis | Chief Medical Officer |
Nov 25 '24 |
Sale |
0.57 |
565 |
322 |
111,110 |
Mohideen Pharis | Chief Medical Officer |
Nov 22 '24 |
Sale |
0.53 |
342 |
181 |
111,675 |
Mohideen Pharis | Chief Medical Officer |
Nov 21 '24 |
Sale |
0.54 |
2,350 |
1,269 |
112,017 |
Mohideen Pharis | Chief Medical Officer |
Jul 29 '24 |
Sale |
0.98 |
1,785 |
1,749 |
79,367 |
Mohideen Pharis | Chief Medical Officer |
May 24 '24 |
Sale |
1.36 |
660 |
898 |
81,152 |
Mohideen Pharis | Chief Medical Officer |
May 22 '24 |
Sale |
1.38 |
382 |
527 |
81,812 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):